Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Linotroban
Cat. No.:
0225LY-0906
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Linotroban acts as a selective and powerful thromboxane (TXA2) receptor antagonist endowed with antithrombotic properties.
Synonym:
120824-08-0; 2-[5-[2-(benzenesulfonamido)ethyl]thiophen-2-yl]oxyacetic acid; 2-((5-(2-(phenylsulfonamido)ethyl)thiophen-2-yl)oxy)acetic acid; ((5-(2-Benzenesulfonamidoethyl)-2-thienyl)oxy)acetic acid
CAS No.:
120824-08-0
Compound CID:
65940
Formula:
C14H15NO5S2
Formula Weight:
341.4
Specification
Relative Density:
1.411 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Linotroban can be used in hematological research to study the antagonism of thromboxane A2 receptors and their effect on platelet aggregation.
Library Information
Target:
TXAS
Receptor:
TXA2R
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-12
Plate Location:
f6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
